The Lynx Group
Cholangiocarcinoma News

Biliary Tract Cancer

Preliminary data suggest that dual blockade with ipilimumab and nivolumab might have antitumor activity in a subset of patients with microsatellite-stable biliary tract cancer.
Read More

Phase 2 study results suggest that the addition of nivolumab and ipilimumab to chemotherapy as first-line therapy did not provide additional PFS benefit compared to standard-of-care chemotherapy in patients with advanced biliary tract cancer.
Read More

Web Exclusives — May 30, 2020
The combinations of nivolumab with gemcitabine/cisplatin or nivolumab with ipilimumab were tested in patients with untreated advanced biliary tract cancer.
Read More

Web Exclusives — May 30, 2020
The response rate to the combination of ipilimumab and nivolumab in patients with advanced biliary tract cancer compared favorably to clinical trials investigating single-agent anti–PD-1 therapy.
Read More

Web Exclusives — May 30, 2020
Durvalumab ± tremelimumab plus chemotherapy was well-tolerated and showed promising efficacy in chemotherapy-naïve patients with advanced biliary tract cancer.
Read More

Web Exclusives — May 28, 2020
This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer.
Read More

Web Exclusives — May 28, 2020
Varlitinib plus capecitabine was compared with capecitabine plus placebo as second-line treatment in patients with advanced or metastatic biliary tract cancer.
Read More

Web Exclusives — April 23, 2020

San Francisco, CA—Cholangiocarcinoma (CCA), a type of biliary tract cancer, is a rare malignancy, with no FDA-approved medications specifically for this type of cancer. The current standard first-line treatment for patients with locally advanced or metastatic CCA is a chemotherapy combination of gemcitabine and cisplatin.

Read More

Page 3 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: